Rhythm Pharma Q2 revenue $71.3M; RM-718 shows -11.6% BMI reduction in HO

RHYTHM PHARMACEUTICALS, INC.

Q2 2026 IMCIVREE revenue $71.3M, up 19% sequentially; U.S. revenue $51.0M (+38% QoQ).
Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval in March 2026.
RM-718 Phase 2: -11.6% mean BMI reduction at 16 weeks (n=7) in acquired HO, comparable to setmelanotide.
Net loss $(50.4)M ($(0.73)/share) vs $(48.0)M ($(0.75)/share) in Q2 2025.
Cash $330.9M; FY 2026 Non-GAAP OpEx guidance $363M-$397M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.